13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)

Page 3 of 6 – SEC Filing

 

CUSIP No. 253031108

1

Names of Reporting Persons.

Peter Kolchinsky

2 Check the Appropriate Box if a Member of a Group (See Instructions)
(a) [ ]
(b) [ ]
3 SEC Use Only
4

Source of Funds (See Instructions):

AF

5

Check if disclosure of legal proceedings
is required pursuant to Items 2(d) or 2(e):

[ ]

6 Citizenship or Place of Organization.    United States

Number

of Shares

Beneficially

Owned by

Each

Reporting

Person With

7 Sole Voting Power     0
8 Shared Voting Power      4,462,313
9 Sole Dispositive Power     0
10 Shared Dispositive Power  4,462,313
11

Aggregate Amount Beneficially Owned by
Each Reporting Person

4,462,313

12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)     [ ]
13

Percent of Class Represented by Amount
in Row (11)

8.6%2

14

Type of Reporting Person (See Instructions)

HC, IN

2
Represents 4,462,313 shares of the Common Stock of the Issuer which constitutes approximately 8.64% of the class
outstanding. The percentage calculation assumes that there are currently 51,641,738 outstanding shares of the Common Stock of
the Issuer, based on the Issuer’s Form 8-K as filed with the SEC on December 29, 2017.

Follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)